The role of methylprednisolone in severe COVID-19 patients: a meta-analysis.

ABSTRACT:

Background

The purpose of this study is to assess the effectiveness of methylprednisolone in severe COVID-19.

Methods

PubMed, the Cochrane Library and Web of Science were searched for literatures comparing methylprednisolone and control treatment in severe COVID-19 patients. Statistical pooling was reported as risk ratio (RR) with corresponding 95% confidence interval (CI). The outcomes of interest in the literature survey were mortality and adverse events.

Results

A total of 13 studies were included, including 3,138 patients with severe COVID-19, of which 1,634 patients were treated with methylprednisolone and 1,504 patients were treated with control treatment. Five of the 13 studies reported severe adverse events. Our meta-analysis indicates that methylprednisolone

SUBMITTER: Xu W 

PROVIDER: S-EPMC11341412 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature